Caredx reports third quarter 2023 results

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) — the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported financial results for the third quarter ended september 30, 2023. third quarter 2023 highlights reported revenue of $67.2 million, an increase of 7% over the second quarter of 2023, excluding approximately $7.8 million related to m.
CDNA Ratings Summary
CDNA Quant Ranking